TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be 21 years old or older.~* Must be able to provide finger stick and venous whole blood samples.~* Must be able to understand and sign a consent form.~* Must be able to provide an additional sample(s) required by the study site for an additional FDA EUA authorized antibody testing (ELISA, CMIA, or other antibody test).~* Has an immediate need to determine COVID-19 status for occupational purposes.~* Was exposed to a COVID-19 patient within 7 days that leads the healthcare provider to suspect the individual of possibly having SARS-CoV-2 infection.~* Has symptoms that lead the healthcare provider to suspect the individual of possibly having SARS-CoV-2 infection.~* Has had a positive FDA EUA authorized PCR test between 1-28 days with or without symptom expression.~* Individuals who have tested positive for COVID-19 infection and have antibodies detected must have agreed to participate in the MCW Tissue Bank COVID-19 banking project.~Exclusion Criteria:~* Is receiving treatment with infusion of convalescent plasma or other antibody therapy related to SARS-CoV-2 infections.~* Tested negative for COVID-19 by PCR more than 7 days ago.~* Is participating in a SARS-CoV-2 vaccine study.or received any doses of the available SARS-CoV-2 vaccines.~* Previously tested positive for COVID-19 at any point in time (for asymptomatic patients enrolling in the negative patient population).

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Antigen testing in those who have history of COVID-19 (Type: None): Individuals must have had history of COVID-19. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
- Antigen testing in those who do not have history of COVID-19 and COVID immunization (Type: None): Individuals may not have history of COVID-19 and COVID immunizations in order to be eligible. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sinusitis and Facial Pain Disorders Anti-Depression Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meet diagnostic criteria for chronic sinusitis~* meet diagnostic criteria for facial pain disorder~* meet criteria for major depressive disorder on the PHQ-9~* 18 years of age or older~* established primary care provider~* able to read and speak English~Exclusion Criteria:~* unable to give informed consent of unable to complete self-administered questionnaires due to cognitive impairment, language barriers or severe medical condition~* terminal illness or significantly immunocompromized~* complications from chronic rhinosinusitis~* presence of sinus tumor~* isolated sphenoid disease~* immotile cilia syndrome~* currently on anti-depressant or mood stabilizer med.~* diagnosis of bipolar disorder, schizophrenic disorders, paranoid disorders, or psychotic disorders NOS~* significant suicide risk~* history of hospitalization for mental disorders including psychosis or depression~* history of drug abuse within prev. 6 months or dependency on any drug, including alcohol~* pregnant or breast feeding~* women of child-bearing potential not currently using an approved method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): escitalopram 10mg - 30mg daily
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to the ICU in septic shock~* All patients that develop septic shock while in the ICU~Exclusion Criteria:~* Age less than 14 years~* Pregnancy~* Estimated life expectancy (due to comorbidities) less than 90 days~* Presence of relative or absolute contraindications to CPFA~* Admission from an other ICU where the patient remained for more than 24 hours~* Absence of informed consent

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High doses CPFA (Type: EXPERIMENTAL): High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
- Control group (Type: NO_INTERVENTION): standard practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have signed written informed consent~2. Be male and/or female outpatients 18 65 years of age, inclusive~3. For women: must be surgically sterile, 2 years postmenopausal, or, if they have childbearing potential, using a medically accepted method of birth control and agree to continue use of this method for at least 30 days after the last dose of study drug (i.e., barrier method with spermicide, steroidal contraceptive or intrauterine device \[IUD\])~4. Meet DSM IV1 criteria for major depressive episode (unipolar), with atypical features~5. Have a score of 20 or greater on the Hamilton Depression Rating, 28-item version (HAM-D-28)~6. Have a complete medical and psychiatric history, physical examination, laboratory evaluation, and ECG before study entry.~7. Have baseline laboratory values and ECG that are normal, or abnormalities that are clinically insignificant~Exclusion Criteria:~1. Have significant and/or unstable gastrointestinal, neurological, endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease; organic brain disease; or cancer as determined by history, physical, ECG, and laboratory examination~2. Have a history of peptic ulcer disease~3. Have a history of severe asthma~4. Have a current diagnosis of pheochromocytoma~5. Are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not practicing medically acceptable birth control. (A blood pregnancy test will be performed at the screening visit)~6. Meet criteria for DSM IV1 psychoactive substance abuse or dependence in the past month~7. Have a history of a psychotic disorder~8. Use any medications that, in the judgment of the investigator, might have psychotropic effects, or interact unfavorably with betahistine dihydrochloride including centrally acting antihistaminic agents~9. Have a history of hypersensitivity to betahistine dihydrochloride~10. Exhibit, or suggestion that they may display, behavior that will not be conducive to the study procedures~11. Are at significant risk of suicide as indicated by a score of 3 or greater on item number 11 on the HAM-D 28~12. Have received any investigational product within 28 days of Screening~13. Have used any antidepressant within 7 days of Screening (14 days for MAOIs; 21 days for fluoxetine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Betahistine dihydrochloride (Type: EXPERIMENTAL): Oral betahistine dihydrochloride; daily dose 50-300 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 years~* Acute medical disease requiring thromboprophylaxis according to international guidelines~* Anticipated immobilization of at least 4 days~* Renal insufficiency defined by creatinine clearance between 20 and 50 mL/min according the MDRD formula~* Written informed consent~Exclusion Criteria:~* Active bleeding or bleeding in the previous 3 months~* Known bleeding diathesis~* Platelet count \< 100.000~* Ongoing treatment with unfractionated heparin, low molecular weight heparin, fondaparinux, or vitamin K antagonists~* Use of prophylactic doses of heparin, low molecular weight heparin, or fondaparinux in the previous 72 hours~* Life expectancy \< 1 month

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fondaparinux (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of osteoarthritis of the knee~* Have moderate to severe pain based on a trial questionnaire~* Must be on a stable dose of pain medication for 4 weeks before entering the trial~* Medically stable condition~Exclusion Criteria:~* History of joint replacement surgery in the affected joint or planned surgery involving the affected joint during the trial~* Diabetes mellitus~* Uncontrolled cardiovascular disease or hypertension~* Previous treatment with another investigational NGF inhibitor therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-42160443 (lower dose) (Type: EXPERIMENTAL): None
- JNJ-42160443 (higher dose) (Type: EXPERIMENTAL): None
- Oxycodone CR (standard pain medication) (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. PD patients (aged ≥18 years) are dialyzed with lactate-buffered glucose dialysate, using a twinbag connection system (Baxter Healthcare, Guangzhou, China).~2. For entry , all patients are required to meet all diagnositic criteria of the International RLS Study Group (IRLSSG), to have a baseline total score \>15 on the Study Group's International RLS Rating Scale (IRLS), and to have experienced RLS symptoms at least 2-3 days per week throughout the perior 3 months.~3. Each patient should write informed consent.~4. All patients are required to be interviewed to the frequency required by the research process.~Exclusion Criteria:~1. Patients with severe gastrointestinal illness can not tolerate oral drugs.~2. Patients who work on a shift schedule are not allowed to participate.~3. Women with childbearing potential are excluded for pregnancy, inadequate contraception, or current breastfeeding of a child.~4. Patients are also excluded for current use (within 14 days before baseline) of medications that might affect RLS symptoms, e.g., levodopa, dopamine agonists or antagonists, hypnotics, lithium formulations, or antidepressants.~5. Patients with serum ferritin ≤200 ng/ml, or Hb \<110g/L, or Kt/V \<1.7 are excluded.~6. Patients with severe and unstable inflammation disease (active systemic infection, acute cardiovascular disease, active liver disease, active connective tissue disorder, ,and cancer within 1 year of radiotherapy and chemotherapy, )

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Peritoneal dialysis patients diagnosed with restless legs syndrome will receive pramipexole.
- Control group (Type: PLACEBO_COMPARATOR): Peritoneal dialysis patients diagnosed with restless legs syndrome will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Negative Pressure Dressing Therapy in Soft Tissue Sarcoma Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults undergoing primary soft tissue sarcoma excision which is primarily closed.~Exclusion Criteria:~* Unable to consent~* Children~* Post radiation sarcomas or sarcoma in presence of active infection~* Multiple metastatic disease~* Presence of Endoprosthesis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Negative Pressure Wound Therapy (Type: EXPERIMENTAL): 120 hours of negative pressure wound therapy (ActiVAC, KCI) applied to a primarily closed ('acute') wound.
- Standard dressings (Type: ACTIVE_COMPARATOR): Absorbant dressings applied in a standard fashion, i.e. only changed as necessary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All residents of the nursing home facility, (M/F) 65 years or above, who have recently tested positive through Ohio's PARRT Program are eligible~* Resident must submit weekly nasal swab sample per nursing home COVID testing guidelines~* Clinical suspicion of a new episode of acute respiratory tract infection.~* Laboratory confirmed SARS-CoV-2 infection by either a laboratory test, PCR or any other commercial or public health test~Exclusion Criteria:~* Nursing home residents that are not taking part regularly in weekly screening for SARS-COV-2 or residents that test negative through Ohio's PARRT program cannot be included as part of study analyses~* Residents on hospice, residents currently intubated, residents with scheduled transfer to another nursing home facility will not be included in study analyses

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients with New Cases of SARS-CoV-2 (Type: None): Newly recruited residents who have been identified as positive through Ohio's Post-Acute Regional Rapid Testing (PARRT) Program will undergo at at least 4 weeks, but no more than 8 weeks, of nasal swab and exhaled breathe particles specimen collection for Covid testing. Previously enrolled residents will submit weekly collections of nasal swab specimens and exhaled breathe particles once they exhibit respiratory-related symptoms, or once a test is ordered by the provider for suspicion of exposure. Collection will continue until these subjects fulfill their 8 weeks of testing.
- Patients without SARS-CoV-2 (Type: None): This cohort will consist of previously enrolled residents who submitted nasal swabs and exhaled breathe particles for Covid testing once a week for 8 weeks. The patients will have been identified as negative for a SARS-CoV-2 infection each week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by the patient and guardian.~* Positive clinical history of allergy to dust mites.~* FEV1 greater than or equal to 80% of the expected value and improvement in FEV1 greater than 12% after bronchodilation.~* Age-between 5 and 14 years.~* Sensitization to dust mites, diagnosed by positive skin tests to Dermatophagoides pteronyssinus: wheal size \> 3 mm diameter and / or RAST (\> 0.7 kU / L).~Exclusion Criteria:~* Patients out of the age range.~* Use of immunotherapy during the last four years.~* Any contraindication for the use of immunotherapy in accordance with European Allergy and Clinical Immunology Immunotherapy Subcommittee criteria:~  * Treatment with ß-blockers~ * Patients who have a condition in which adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc..).~ * Coexistence of immunopathological diseases (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role~ * Patients suffering from immune deficiencies~ * Patients with serious psychiatric / psychological disturbances~* Patients aspirin intolerance

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Subcutaneous administration
- B (Type: EXPERIMENTAL): Sublingual administration
- C (Type: PLACEBO_COMPARATOR): Sublingual administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Gastric and Post Pyloric Tube Feedings in Children With Bronchiolitis Requiring High Flow Nasal Cannula

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- All admitted patients for bronchiolitis requiring high flow nasal cannula therapy at Children's Memorial Hermann~Exclusion Criteria:~* Patients with craniofacial abnormalities that prevent tube placement.~* Patients requiring CPAP and mechanical ventilation are also excluded from the study.~* Patients with past surgeries compromising esophageal sphincter tone such as fundoplication or congenital diaphragmatic hernia surgery are excluded.~* Patients transferred to and from PICU are also excluded from the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- nasogastric tube (NGT) feeding (Type: ACTIVE_COMPARATOR): None
- nasoduodenal tube (NDT) feeding (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 ans.~* Metastatic breast cancer or locally advanced~* RE+, HER2-~* Patient receiving paclitaxel-bevacizumab first line chemotherapy~Exclusion Criteria:~* Previous treatment by exemestane (both in adjuvant or metastatic treatment).~* 1st line of chemotherapy different thaan paclitaxel-bevacizumab.~* Treatment by paclitaxel-bevacizumab \> 18 weeks.~* HER2 positifs et/ou récepteurs aux oestrogènes négatifs.~* Previous thrombosis event within the 6 months before inclusion .~* Previous significant surgery within the 28 days before treatment start~* Previuous coagulopathy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- paclitaxel-bevacizumab (Type: ACTIVE_COMPARATOR): Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
- exemestane-bevacizumab (Type: EXPERIMENTAL): exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy